VP candidate stokes misleading claims about fentanyl-laced marijuana
A New York representative shares concerns about carfentanil, and the DEA warns about xylazine.
We surveyed 246 health care providers in August 2024, just before the FDA approved updated COVID-19 vaccines. Here’s what we learned.
Full storyInfodemiology in action
A New York representative shares concerns about carfentanil, and the DEA warns about xylazine.
This week, false claims about infant hepatitis B and COVID-19 vaccines circulated while regional debates about vaccine mandates and the summer COVID-19 surge persist.
Our partners
Real-time intelligence on the health narratives trending nationally, regionally, and by state.
Contextualizing trending narratives across the nation's most pressing health topics.
The first U.S.-based trainings on infodemiology for public health professionals and health care providers.
JMIR FEED
Featured trainings and resources